Ординатура / Офтальмология / Английские материалы / Clinical Ocular Pharmacology 5th edition_Bartlett, Jaanus_2008

Index

787

Resistance

Retinal disease—cont’d

Roundworm, 629-630, 629f

bacterial, 177-179

rostaporfin in, 305

Route of administration, 4, 703

to cephalosporin, 183

verteporfin in, 303-305

Ruboxistarurin, 311-312

to fluoroquinolone, 194, 448

progressive outer necrosis, 624-626,

Rule

corneal ulcers and, 523

625f, 625t

Clark’s, 11

to sulfonamides, 193

ruboxistaurin for, 311 -312

professional standard, 66, 66b

Respiratory depression, 107

sarcoidosis as, 630-632, 631f

Rust ring, corneal, 499, 500f

Restasis, 241

squalamine for, 311

Rx symbol, 55

for tear stimulation, 276

VEGF trap for, 310-311

S

Retaane

Retinal hemorrhage in sarcoidosis, 632

for age-related macular degeneration,

Retinal nerve fiber, 676-678, 678f

Sabouraud’s agar, 441

639

Retinal photography, 676-677

Sabril, 752t

intravitreal, 35t

Retinal vaso-occlusive disease, 472

Sac, lacrimal, 417-418

Retention cyst, of eyelid, 401-402, 401f

Retinal vein occlusion, 632, 634

Saccadic velocity study, in thyroid

Retina

Retinitis, cytomegalovirus, 50-51

disease, 649

drugs affecting, 725-736, 725t

Retinitis pigmentosa, vitamin A in, 300

Salicylate, 98-100, 99t

aminoglycosides, 189

Retinochoroiditis, 587. See also Posterior

adverse effects of

antineoplastic agents, 731-733,

uveitis

on conjunctiva, 713

732f, 733b

bird-shot, Cyclosporine A for, 241

on eyelid, 713

cardiac glycosides, 729, 729b, 730f

toxoplasmic, 626-629, 626f, 627f

clinical uses of, 99

chloroquine, 725-728, 725t, 726f, 727t

pyrimethamine for, 193

common aspirin products, 99t

clomiphene, 731

Retinoid, 751t

contraindications to, 100

hydroxychloroquine, 725-728, 725t,

optic nerve and, 740

pharmacology of, 98

726f, 727t

Retinopathy of prematurity, 334

side effects of, 99-100

inhaled corticosteroids, 734

Retinoscopy, 345, 347

Salmonella

isotretinoin, 733-734

Retisert

infections caused by, 178t

nonsteroidal anti-inflammatory

intravitreal, 35t

Reiter’s syndrome and, 472

drugs, 731

for retinal disease, 309

SANA study, 307

oral contraceptives, 730-731

for uveitis, 594

Saquinavir, 207t

quinine, 734

Retrobulbar anesthesia, 603

Sarcoidosis, 630-632, 631f

sildenafil, 729-730

Retrobulbar injection, 49, 49b

Scanning laser ophthalmoscopy,

talc, 734-736, 735f

Retrotarsal block, 324, 327f

confocal, 679, 679t

thioridazine, 728-729, 728f

Retrovir, 206t

vigabatrin, 733

Rev-Eyes, 121

Scarring

structure of, 24

Reyataz, 207t

of Bowman’s layer, 491f, 492

toxoplasmosis and, 217

Reye’s syndrome, 100

Retinal circulation, 164

Rheumatoid arthritis, 580

Schirmer I test, 420-421

Retinal detachment

Rhytid, 409

anesthesia for, 322

misdiagnosis of, 74-75

Rifabutin, 716, 716t, 754t

Schirmer II test, 421, 423-424

pilocarpine and, 169, 170

Rifampin, in fungal keratitis, 536

Schnyder’s dystrophy, 485t

postoperative, 614-615, 614f

Rimexolone

Sclera

in uveitis, 588

clinical uses of, 229

Retinal disease, 303-315, 617-642

in episcleritis, 578

structure of, 19-22, 20f, 21f, 21t

angiogenesis and, 305-306

formulations of, 227t

vasculature of, 575

corticosteroids for, 308-310

Ring

Scleritis, 579-585

cytomegalovirus causing, 621-624,

Fleischer’s, hydrops and, 491f

classification of, 579f

621f, 622f, 622t

rust, 499, 500f

diseases associated with, 577b

fluorescein angiography in, 617-619,

Risedronate, 753t

fluorometholone for, 228

618f

Risk, disclosure of, 67-69, 68f, 69f

glaucoma with, 694

indocyanine green angiography in,

Risk analysis in glaucoma treatment, 686

laboratory testing in, 582, 583t

619-620

Ritalin, 718

management of, 583-584

macular, 632-639

Ritonavir, 207t

overview of, 579-581

age-related macular degeneration

Rituximab, 471

posterior, 582-584, 583f

as, 635-639, 635f, 636f

Rocephin, 184t

Sclerokeratitis, 582, 582f

cystoid macular edema as, 632-635,

Rod, gram-negative, infections caused

Scleromalacia perforans, 581

633f

by, 177

monoclonal antibodies for, 306-308

Rofecoxib, 751t

Scopolamine, 130

necrotizing herpetic, 620-621, 620f

Rosacea, 463-465, 464ft

adverse effects of, 718

parasitic, 626-630

blepharitis in, 388-389, 388f

toxocariasis as, 629-630, 629f

Rose bengal, 289-290, 289f, 290f, 422

361-362

toxoplasmosis as, 626-629, 626f, 627f

in exposure keratopathy, 508f

characteristics of, 345t

photodynamic therapy for, 303-305

Rostaporfin, 305

for corneal abrasion, 497

788

Index

Scopolamine—cont’d

Sign, Hutchinson’s, 455, 456f

SofZia, 31

preparations of, 127t

Sildenafil, adverse effects of, 749t

Solid delivery device, 45-47, 46f, 47f

properties of, 127t

on optic nerve, 738-739

collagen shield as, 46-47, 46f

for pseudophakic cystoid macular

retinal, 729-730

cotton pledgets as, 46, 46f

edema, 614

Silicone hydrogel contact lens, 509

filter paper strips as, 46, 46f

in Reiter’s syndrome, 473

Silicone oil, 495

soft contact lens as, 45-46

Scotoma, 157

Silicone plug, 273, 273t, 426-427, 428f

Solution

Scrapings, conjunctival, 442-443

Silver nitrate

instillation of, 40-42, 41b, 41f, 42f

Screening for drug-induced retinopathy,

ophthalmia neonatorum and, 462

packaging of, 39

727t

for superior limbic

storage of, 39-40

Scrub, lid, 45, 46t

keratoconjunctivitis, 476

unit-dose dispensers of, 42, 43f

Scurf, 383, 383f, 384, 385f

Simvastatin, 749t

SOM230, 659

Seasonal allergy, 228, 550, 556t, 560-561

Sixth nerve palsy, 666-669

Somatostatin analogue, 658-660

560f

Sjögren’s syndrome, 425

Soothe, 427t

Sebaceous cyst of eyelid, 401-402, 401f

Skin

Soriatane, 751t

Sebaceous gland carcinoma, 404, 404f

anesthesia of, 94

Sparfloxacin, 194t

Seborrhea, meibomian, 386-387

beta-blockers affecting, 148b

Spasm, hemifacial, 376-379, 376f, 378t

Seborrheic blepharitis, 385-386, 385f, 386f

steroid-induced depigmentation of,

Spectacles, 347-348

dry eye and, 425

390-391

Spectrum of drug activity, 175

Seborrheic-staphylococcal blepharitis,

Skin disorder

Spray

385

methazolamide and, 164

administration of, 43-, 43f

Sebum in seborrheic blepharitis, 385

staphylococcal infection as, 177

cycloplegic, 346-347

Secretion, meibomian gland, 386-388,

sulfonamides causing, 194

for pupil dilation in child, 334

387f

Skin testing, 560

Spring catarrh, 550. See also

Secretory system

Sleep test for myasthenia gravis, 374-375

Conjunctivitis, allergic

anatomy and physiology of, 415-417,

Slit-lamp examination

Spud, 499, 499f

416f, 417f

in Adie’s syndrome, 359

Squalamine, 311

evaluation of, 419-420

in anisocoria, 350

Squamous epithelium, stratified, 437-438

Sector dilation, 337, 337f

of anterior angle, 330, 331f, 332f

Squamous metaplasia, membrane, 271

Sedation, antihistamines and, 254

in band keratopathy, 495

Stability of drug, 28

Sedative, opioid as, 107

of corneal abrasion, 497

Stabilized oxychloro-complex

Seidel’s sign, 607

of corneal ulcer, 521

in artificial tears, 270

Seidel’s test, 604, 604f

in exposure keratopathy, 508

effects of, 30-31

Seizure, 133

in interstitial keratitis, 516

Stain

Selegiline, 690t

phlyctenular keratoconjunctivitis

Giemsa, 535

Self-abusive behavior, 480

and, 517

Gram

Sensorineural hearing loss, 192

in phthiriasis palpebrarum, 398

in conjunctival inflammation,

Sensory nerve of eyelid, 324f

SLUDGE, 666

443, 443t

Serratia marcescens

SmartPlug, 429t

in fungal keratitis, 535

aminoglycosides for, 187

Smear, conjunctival, 442-443, 443t

lissamine green, 508f

chronic conjunctivitis and, 451

Smoking and thyroid disease, 644, 652

patterns of, 515b

corneal ulcer and, 520

Social history, 4t, 6

rose bengal, 508f

infections caused by, 177, 178t

Sodium, 159

Standard

Serum test in myasthenia gravis, 374

Sodium ascorbate, 511

of care, 71-73

Seventh cranial nerve, 425

Sodium channel, 151

professional community, 66, 66b

Severe pain

Sodium chloride

reasonable patient, 66, 66b

in child, 109-110

for corneal edema, 279-280, 280t, 281f

Staphylococcus

in elderly, 110-111

in Fuchs’ dystrophy, 489

conjunctivitis and, 448

Sexually transmitted disease

Sodium chondroitin sulfate, 495

corneal ulcer and, 521t

azithromycin for, 192

Sodium ethylene diaminetetraacetic

erythromycin for, 191

erythromycin for, 191

acid, 495

phlyctenulosis in, 475

tetracycline for, 190

Sodium fluorescein, 422

Staphylococcus aureus

Shadow test

Sodium hyaluronate, 33, 268

aminoglycosides for, 187

for anterior angle evaluation, 330,

Sodium perborate, 30, 270

azithromycin for, 192

331f, 332f

Soft contact lens

in bacterial conjunctivitis, 446

cycloplegic refraction and, 344

in bullous keratopathy, 494

blepharitis and, 382-383, 384

Shield, collagen, 46-47, 46f

for drug delivery, 45-46

canalicular infection with, 433

Shiner, allergic, 560

epithelial microcysts and, 543

cephalosporin for, 183

Shingles, 393-397, 394f, 396f

in Fuch’s dystrophy, 489

chronic conjunctivitis and, 451

Sickle cell disease

in thyroid disease, 653

clarithromycin for, 192

acetazolamide and, 163

Soft tissue in thyroid-related

in conjunctival flora, 438

intraocular pressure and, 692-693

orbitopathy, 647-648, 648f, 655

for conjunctivitis, 447

790

Index

Syphilis

Tearing, management of, 715

Thiazolidinedione, 660

drugs for, 176t

Tears

Thiel-Behnke dystrophy, 484t

interstitial keratitis in, 516t

adverse drug effects on, 713-715, 714t

Thimerosal, 474

penicillin for, 181

artificial, 266-272. See also Artificial

Thioglycolate broth, conjunctival

uveitis and, 598

tears

culture for, 441

Systane, 267t, 427t

compartment theory and, 25-26

Thioridazine

Systemic Avastin for Neovascular AMD

epiphora and, 429-432, 430f, 431f,

adverse effects of, 756t

study, 307

432f

retinal, 728-729, 728f

Systemic disease

structure of, 17-19, 18f

antimuscarinic dosage of, 721t

conjunctivitis with, 459, 460t

Tears Naturale, 267t, 427t

Third nerve palsy, 360-361, 361f

episcleritis with, 576b

Tegison, 751t

Thorazine, 756t

uveitis with, 588b

Tendonitis, 195

Thygeson’s superficial punctate

Systemic drug, adverse reaction to,

Tenofovir, 206t

keratitis, 241-242, 533-534

701-759. See also Adverse

Tensilon test for myasthenia gravis, 374

Thymectomy, 375

reaction

Test

Thymoxamine, 119

Systemic lupus erythematosus

forced duction, 320-321, 321f

Thymus gland, 373

conjunctiva in, 459, 460t, 472-474, 473f

in Horner’s syndrome

Thyroid disease, contraindications

drug-induced, 740, 740b, 741b

apraclonidine, 355-356

related to, 5

T

cocaine test in, 355, 356f, 357t

Thyroidectomy, 652-653

hydroxyamphetamine, 355-356,

Thyroid-related orbitopathy, 643-662

T lymphocyte in thyroid disease, 645

356f, 357t

classification of, 645-650, 646t, 647f-

Tacrolimus

phenylephrine, 356-357

650f, 649t

for atopic dermatitis of eyelid, 570

sweat, 354

clinical course of, 651-652

for psoriasis, 465

for myasthenia gravis, 344, 374

clinical presentation of, 643-644

for uveitis, 595

phenol red thread, 421

epidemiology of, 644-645

Tadalafil, 729-730, 749t

Schirmer I, 421-422

etiology of, 645

Talc, 734-736, 735f

anesthesia for, 322

imaging of, 650-651, 651f

Tamoxifen, 753t

Schirmer II, 422, 423-424

laboratory studies for, 644

cornea and, 704t

shadow

management of, 652-661, 661t

retina and, 731-732, 732f

for anterior angle evaluation, 330,

of corneal involvement, 656-657

Tamsulosin, 716-717, 716t, 748t

331f, 332f

of extraocular muscle, 656

TAP study, 304

cycloplegic refraction and, 344

of eyelid retraction, 653-655, 654f

Tarsorrhaphy

Test strip, 422f

of optic neuropathy, 657

cyanoacrylate, 408

Tetracaine

orbital decompression in, 660-661,

lateral, 427-428

abuse of, 513-514

660f

Tavist, 251t

as topical anesthetic, 88-89, 88t

orbital irradiation in, 660

Tazarotene, 465

Tetracycline, 190-191, 190t

plasmapheresis in, 658

Tazicef, 184t

adverse effects of, 754t

of proptosis, 656

Tazidime, 184t

on conjunctiva, 713

of soft tissue involvement, 655-656,

Tazobactam, 180t

on optic nerve, 739-740

655f

Tear breakup time, 421-422

on sclera, 718

somatostatin analogues in,

Tear conservation, 426-428, 428t

in blepharitis, 388

658-660

lacrimal occlusive devices for, 273-274,

in burn injury, 511

systemic steroids in, 657-658, 659f

273f, 274f

classification of, 189t

of thyrotoxicosis, 652-653

ointments for, 272-273, 272t

clinical uses of, 190

Thyroid-stimulating hormone, 644

Tear film

for conjunctivitis, 447

Thyrotoxicosis, 648-649

abnormality of, 264-276

for meibomian gland infection, 387

management of, 652-653

after refractive surgery, 265

for pathogens susceptible to, 442t

Thyroxine, 644

artificial tears for, 266-272. See also

pharmacology of, 189

Ticarcillin

Artificial tears

phlyctenular keratoconjunctivitis

for pseudomonal infection, 182

etiology of, 264-265

and, 518

spectrum of activity of, 180t

tear conservation for, 272-274, 272t,

in phlyctenulosis, 475

Tight junction in uveitis, 588

273f, 273t, 274t

pigmentation caused by, 713, 718

Timolol

tear stimulation for, 274-276

in recurrent corneal erosion, 506

brimonidine and, 156f

composition of, 416-417, 417f, 419t

in Reiter’s syndrome, 473

clinical uses of, 148

evaluation of, 420-422, 420f, 421b,

for rosacea, 464

contraindications to, 149-150

422f, 422t, 423f

for trachoma, 458

dorzolamide with, 166-167

structure of, 263-264, 264f

Tetrahydrozoline, 247, 248t, 249

formulations of, 146t

Tear stimulation, 272-276

in episcleritis, 578

for glaucoma, 689t

Tear supplementation, 266-272. See also

TheraTears, 267t

pharmacology of, 145-147

Artificial tears

Thermal cautery, 409-410

side effects of, 148-149, 149b, 149f

Tear volume test, 422, 422f, 422t

Thiabendazole, 630

Timoptic, 146t

Index

791

Tinted contact lens in thyroid-related

Topical anesthesia—cont’d

Treatment of Age-related Macular

orbitopathy, 655

Schirmer No. 1 test, 322

Degeneration Study, 304

Tipranavir, 207t

ultrasonography, 321

Treponema pallidum

TobraDex, 464

mydriatic instillation and, 333

infections caused by, 177

Tobramycin

treatment requiring, 322-323, 323b, 323f

penicillin for, 181

in bullous keratopathy, 494

Topiramate, 752t

uveitis and, 598-599

in burn injury, 510

intraocular pressure and, 724

Tretinoid, 751t

clinical uses of, 189

myopia caused by, 721

Tretinoin ointment, 271

formulations of, 186t

Topomax, 752t

Triamcinolone acetonide

steroids with, 188t

Toxic conjunctivitis, 474

for chalazion, 390

for corneal ulcer, 523

Toxic epidermal necrolysis, 469-470

in cystoid macular edema, 633

for infectious conjunctivitis, 446

Toxic keratitis, 513-514, 514f

for pathogens susceptible to, 442t

Toxic optic neuropathy, 300

intravitreal administration of, 50,

in recurrent corneal erosion, 505, 507

Toxicity. See also Adverse drug reaction

308-309

Tobramycin-dexamethasone, 464

of atropine, 129

Tolbutamide, 194

of local anesthetic, 90-91, 90f, 91f

edema, 614

Tolerance to timolol, 145-146

minimizing of, 7

Toloxatone, 690t

of NSAIDs, 259

for uveitis, 594

Tometin, 109t

penicillin causing, 182

Trichiasis, 405-406, 406f

Tomography

of pilocarpine, 169

Trichophyton, 391

anterior segment ocular coherence,

of tetracycline, 190-191

675

Toxin, botulinum, 666-669, 667b

and, 117

computed

for blepharospasm, 377-379, 378f,

Trifluridine, 197

in myasthenia gravis, 375, 375f

378t

guidelines for, 198t

in thyroid-related orbitopathy,

Toxocariasis, 629-630, 629f

650-651, 651f

Toxoplasma gondii, 217

Triiodothyronine, 644

optical coherence

Toxoplasmosis, 626-629, 626f, 627f

Trimethoprim

in glaucoma, 679, 679t

pyrimethamine for, 193

clinical uses of, 193

in uveitis, 599

Trabecular meshwork

for conjunctivitis and, 447

Tonicity agent, 31b

anticholinergics and, 722

contraindications to, 194

Tonometry, 671-674, 673b

corticosteroids and, 724

formulations of, 187t

alternatives to, 673-674

Trabeculitis, 694

anesthesia for, 320

Trachoma, 457-458, 458f

pharmacology of, 193

in anterior uveitis, 591

Tramadol

side effects of, 193-194

dynamic contour, 674

formulations of, 105t

Trimethoprim-polymyxin B

errors with, 674b

pharmacological properties of, 106

for conjunctivitis, 447

fluorescein sodium for, 286, 287t

Transplacental transmission of

for infectious conjunctivitis, 446

in intermediate uveitis, 592

Toxoplasma gondii, 626

Trimethoprim-sulfamethoxazole

in posterior uveitis, 593

Transplantation, limbal stem cell, 468-469

in preseptal cellulitis, 391

testing of, 7

Transport, active, 26-27

for toxoplasmosis, 628, 629

Tooth, tetracyclines affecting, 190

Transporter, retinal, 24t

Trizivir, 206t

Topical administration, 47-48, 48f

Trantas’ dots, 565-566, 565b, 565f

gel for, 45

Tranylcypromine, 690t

Tropicacyl, 127t

lid scrubs for, 45, 46t

Trauma

Tropicamide, 133-137

ointment for, 43-45, 44f

conjunctival, 478-480, 479f

administration, 346

solid, 45-47, 46f, 47f

corneal

in cardiac disease, 340

solution as, 39-42

abrasion as, 44, 496-498, 496f, 497f

clinical uses of, 135-136

sprays for, 43-, 43f

burn as, 509-511, 510f, 510t

suspension as, 39-42

dellen and, 512-513, 513f

contraindications for, 137

Topical anesthesia, 87-90, 88t, 89f, 319-328

exposure keratopathy and, 507-509

for corneal abrasion, 497

abuse of, 513-514

foreign body causing, 498-502,

dapiprazole and, 120

clinical uses of, 319-320

498f-502f

hydroxyamphetamine and, 118

complications of, 75

penetrating, 502-504, 502f, 503f, 504f

for infant or child, 334

for diagnostic procedures, 320b

photokeratitis with, 511-512

pharmacology of, 133-135, 133f,

abrasion evaluation, 320

recurrent erosion and, 486, 487,

135t

applanation tonometry, 320

504-507, 504f, 507f

phenylephrine with, 115-116

contact lens fitting, 322

toxic keratitis and, 513-514, 514f

preparations of, 127t

cultures, 320

iris, 362

properties of, 127t

forced duction test, 320-321, 321f

negligence causing, 71

side effects of, 137

lacrimal drainage, 322, 322f

pain management in, 109

Trusopt. See Dorzolamide

pachymetry, 321, 322f

Travatan, 687-688, 687t

Truvada, 206t

pre-drug instillation, 322

Travoprost, 143-144, 687-688, 687t

Tryptase-containing mast cell, 549

792

Index

Tuberculosis

Uveitis—cont’d

VEGF Inhibition Study in Ocular

interstitial keratitis in, 516t

epidemiology of, 588-589

Neovascularization, 306

phlyctenular keratoconjunctivitis

episcleritis and, 578

VEGF Trap, 35t, 310-311

and, 517

etiology of, 588

Vehicle for drug administration, 31-34

phlyctenulosis in, 475

fluorescein angiography for, 599

Vein occlusion, retinal, 632, 634

Tumor

glaucoma with, 694

Velosef, 184t

Horner’s syndrome caused by, 353

imaging studies of, 599

Vernal keratoconjunctivitis, 549, 557t,

lacrimal gland, 424

intermediate, 591-592

559t, 564-566, 565f

Tumor necrosis factor-a inhibitor, 716t,

complications of, 596-597

cyclosporine A for, 241

717

laboratory tests for, 597-599, 598t, 599b

mast cell stabilizers for, 255

Twitching of eyelid, 407-408

management of, 593-596, 596f

Verruca, 399-400, 400f

Tylosis ciliaris, 383f

corticosteroids in, 593-594, 593b,

Verteporfin, 303-305, 639

Tyndell effect, in anterior uveitis, 590

594b

Verteporfin in Photodynamic Therapy

U

cycloplegic agents in, 594

study, 304

mydriatic agents in, 594

Vertical diplopia, 643

Ulcer

nonsteroidal anti-inflammatory

Vesanoid, 751t

bacterial, 520-525, 521f, 521t, 522f

drugs in, 595

Vesicle, 394-395

contact lens-related, 539, 540t

periocular steroids in, 594-595

Vestibular toxicity, tetracyclines and,

corneal

panuveitis, 593

190-191

bacterial, 520-525, 521f, 521t, 522f

posterior, 592-593

Vfend, 210t

ointment for, 44

complications of, 597

Viagra, 749t

in herpes simplex keratitis, 528

rimexolone for, 229

Vidarabine, 197, 198t-199t

Ulcerative basal cell carcinoma, 403, 403f

Uveitis glaucoma, 631-632

Videoangiography, indocyanine green

Ultrasonography

V

for, 291-292, 291f

anesthesia for, 321

Videx, 206t

in scleritis, 583, 583f

Valacyclovir

Vigabatrin, 733, 752t

in thyroid-related orbitopathy, 650-

clinical indications for, 202t

Vinyl derivative, 268-269

651, 651f

clinical uses of, 201, 202t-203t, 204

Vioxx, 751t

Ultraviolet light in anisocoria testing,

guidelines for, 199t

VIP study, 304

349-350

for herpes simplex keratitis, 530

Viracept, 207t

Ultraviolet radiation burn, 511-512

for herpes zoster conjunctivitis, 456

Viral infection

Unilateral fixed and dilated pupil, 360-362

for herpes zoster ophthalmicus, 532

aspirin and, 100

in adrenergic mydriasis, 362

pharmacology of, 201

conjunctivitis

in anticholinergic mydriasis, 361-362,

Valdecoxib, 751t

adenoviral, 451-454, 452f, 453f,

362f

Valganciclovir, 623-624

453t

damage to iris causing, 362

Vancomycin, 185-186

herpes simplex, 454-455, 455f

in third nerve palsy, 360-361, 361f

endophthalmos and, 606

molluscum contagiosum and,

Unit-dose dispenser, 42, 43f

for methicillin-resistant

458-459, 458f

Unmyelinated nerve fiber, 113

Staphylococcus aureus, 449

nonspecific, 459

Urea in glaucoma, 694

Vanquish, 104t

varicella zoster, 455-456, 456f

Urethritis

Vardenafil, 730, 749t

cytomegalovirus. See also

azithromycin for, 192

Varicella zoster immunization, 396

Cytomegalovirus

in Reiter’s syndrome, 472-473

Varicella zoster virus infection

of eyelid, 393-397

Urokinase-type plasminogen activator, 309

conjunctival, 455-456, 456f

herpes simplex blepharoconjunc-

Urticaria

of eyelid, 393-397, 394f, 396f

tivitis as, 393, 393f

of eyelid, 569t, 571-572

scleral, 584

herpes zoster ophthalmicus as,

sulfonamides causing, 194

Vasoconstrictor, 578

393-397, 394f, 396f

Uvea, 7t, 715-718, 716t

Vascular closure in scleritis, 581, 581f

scleritis with, 577b

Uveitis, 587-599

Vascular disorder, collagen, 580

Viral keratitis, 525-534

anatomy in, 587

Vascular endothelial growth factor,

epidemic keratoconjunctivitis and,

anterior, 590-591, 591t

310-311

525-527, 526f

complications of, 596

in age-related macular degeneration,

herpes simplex, 527-530, 528f, 530f

in interstitial keratitis, 516

635, 638

herpes zoster, 530-533, 531f, 531t, 532f

latanoprost and, 143

VEGF Inhibition Study in Ocular

Thygeson’s superficial punctate,

loteprednol etabonate for, 228

Neovascularization and, 306

533-534

atropine for, 128

VEGF Trap and, 35t, 310-311

Viramune, 206t

classification of, 587

Vascular occlusion, 580

Viread, 206t

complications of, 596-597

Vasculature of sclera and episclera,

Virus

corticosteroid causing, 232

575

conjunctival culture for, 441

cyclopentolate for, 132-133

VasoClear, 248t

as conjunctival pathogen, 439b

diagnosis of, 589-593, 591t

Vasocon-A, 254t, 551t

Visceral larva migrans, 629-630, 629f

diseases associated with, 588b

Vegetative foreign body, 497498

Viscoelastic agent, 268